catechin has been researched along with ono-di-004 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; He, YF; Hu, SS; Jin, J; Wang, D; Wei, W; Wu, YJ | 1 |
| Jin, J; Sun, H; Wang, M; Yang, H; Zhu, S | 1 |
2 other study(ies) available for catechin and ono-di-004
| Article | Year |
|---|---|
Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.
Topics: Alprostadil; Antineoplastic Agents, Phytogenic; Blotting, Western; Bridged Bicyclo Compounds; Caproates; Carcinoma, Hepatocellular; Catechin; Cell Movement; Cell Proliferation; Cell Survival; Dinoprostone; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits, Gq-G11; Hep G2 Cells; Humans; Immunoassay; Liver Neoplasms; Neoplasm Invasiveness; Receptors, Prostaglandin E, EP1 Subtype; Time Factors | 2012 |
Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma.
Topics: Alprostadil; Apoptosis; Carcinoma, Hepatocellular; Catechin; Cell Movement; Cell Proliferation; Dinoprostone; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Receptors, Prostaglandin E, EP1 Subtype; Wound Healing | 2019 |